浙江贝达药业,Beta Pharma,  
浙江贝达药业有限公司成立于2003年1月，是一家由海归团队创办的以自主知识产权创新药物研究和开发为核心，集研发、生产、营销于一体的国家级高新制药企业。

公司在北京设有自己的研发中心，下设合成室、分析室、药理室、制剂室、医学部、知识产权部等，现有90名新药研发人员，包括6位留学归国博士，他们有深厚的专业造诣和国际化的新药开发理念和实践经验，特别是他们都有科技报国，振兴中国医药事业，为民造福，实现自己人生价值的使命和愿望。其中两位博士已入选了中组部“千人计划”，一名博士入选省级的“千人计划”，几位博士先后被评为国家特聘专家、市级特聘专家、“优秀博士后”、“先进科技工作者”。

2006年，公司在杭州余杭建立了自己的生产基地，占地40亩，厂房8000㎡，拥有GMP认证和片剂和膏剂生产车间和原料药、肿瘤口服制剂等11个国药准字号药品生产批文。
公司成立9年来，已成功研发国家1.1 类新药盐酸埃克替尼（凯美纳），部分完成三个国家一类新药的临床前研究，在研新药项目20多项，获国内、国外专利授权两项，申报发明专利41项，获科技部创新基金2项、“863”高科技计划、国家重大新药创制专项资助3项。已成为我国创新药研发的一支新生力量，有望为发展民族制药企业，并逐步走向国际作出相应的贡献。

2010年，公司引进了美国礼来制药战略投资，被众多同行评为“浙商最具投资价值企业”。

2011年，国家一类新药盐酸埃克替尼（凯美纳）获国家食品药品监督管理局颁发的新药证书和生产批文，并于7月份正式上市销售，上市8个月销售收入即突破1亿元人民币。

贝达药业将继续秉承创新、开拓为发展理念，在保持研发优势的同时，力求建立一支国际化的市场、营销队伍，致力于新药研发，将创新的成果、福音带给所有有需要的病人，真正造福国人。

 Zhejiang Beta Pharma is a leading pharmaceutical company primarily focused on the discovery, development and commercialization of new drugs to treat cancer, cardiovascular diseases and diabetes. The company is located in High Tech Park,Hangzhou with R&D center in Beijing.

Zhejiang Beta Pharma is a leading pharmaceutical company with focus on development and commercialization of new drugs for cancer, cardiovascular diseases and diabetes. Conmanna, an EGFR tyrosine kinase inhibitor, for cancer targeting therapy, is our leading compound. The preclinical studies have demonstrated its strong ability to inhibit a varieties of tumor cell growth and very low toxicity to tested animals. The clinical study will start as soon as it gets approval from SFDA.

Beta Pharma has a first-rate research team consisting of 20 multi-disciplined and dedicated professionals, including three American trained doctors. The team has full capacity to carry out the first class research for the new drug development, including chemical synthesis, screening, analysis, scale up, efficacy study, toxicity and safety evaluation and data management. Right now we have three new patented drugs in our pipeline.

We are also processing and marketing generic drugs in collaboration with other pharmaceutical companies including North China Pharma Group. The alliance has dramatically expanded our capacity both for manufacture and marketing.